Crinecerfont decreases glucocorticoid use in adults with congenital adrenal hyperplasia
1. In this randomized controlled trial, twice daily crinecerfont use was associated with reduced daily glucocorticoid use in adults with ...
Tag: glucocorticoid
Crinecerfont facilitates glucocorticoid dose reduction in pediatric congenital adrenal hyperplasia
1. In this randomized controlled trial of pediatric patients with congenital adrenal hyperplasia (CAH), it was found that treatment with ...
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy
1. When comparing corticosteroid peak dose for immunosuppression for anti–PD-1 plus anti–CTLA-4–related adverse events, the HR for OS was 1.66 ...
The 2 Minute Medicine Podcast Episode 29
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
#VisualAbstract: Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure
1. In this pooled analysis of randomized controlled trials, low-dose glucocorticoids taken over a two-year period did not increase patient ...
Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure
1. In this pooled analysis of randomized controlled trials, low-dose glucocorticoids taken over a two-year period did not increase patient ...
Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma
1. Provision of an inhaled glucocorticoid and instruction on its use led to a significantly lower rate of severe asthma ...
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events
Click to read the study in Clinical Cancer Research.
Daily 12 mg dexamethasone not superior to 6 mg for severe COVID-19 infection
1. This multi-centered, randomized controlled trial demonstrated that 12 mg and 6 mg dexamethasone daily had similar efficacy for days ...
#VisualAbstract: Ruxolitinib improved glucocorticoid-refractory chronic graft-versus-host disease
1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy. 2. ...